New pill could shrink rare joint tumors without surgery
NCT ID NCT05059262
First seen Mar 21, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This phase 3 trial tests vimseltinib, an oral drug, for tenosynovial giant cell tumor (TGCT) when surgery isn't possible. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, then all can get the drug. The main goal is to see if the drug shrinks tumors on MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer & Haematology Centre, The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust
London, United Kingdom
-
Centre Léon Bérard
Lyon, France
-
Chris O'Brien Lifehouse
Camperdown, Australia
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Sarcoma Research
Durham, North Carolina, 27710, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
-
Fundacion Jimenez Diaz
Madrid, Spain
-
Helios Klinikum Berlin-Buch
Berlin, Germany
-
Hospital Clinico San Carlos
Madrid, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
-
Institut Bergonié
Bordeaux, France
-
Institut Gustave Roussy
Villejuif, France
-
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
-
Istituto Nazionale Tumori Regina Elena
Rome, Italy
-
Istituto Oncologico Veneto
Padua, Italy
-
Istituto Ortopedico Rizzoli
Bologna, Italy
-
Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Warsaw, Poland
-
Leiden University Medical Center
Leiden, Netherlands
-
Mayo Clinic Rochester
Rochester, Minnesota, 55902, United States
-
McGill University
Montreal, Canada
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10016, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Oslo University Hospital
Oslo, Norway
-
Prince of Wales Hospital
Hong Kong, Hong Kong
-
Princess Margaret Hospital
Toronto, Canada
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
UC Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University College London Hospitals
London, United Kingdom
-
University Hospital Essen (Universitätsklinikum Essen)
Essen, Germany
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Kansas
Kansas City, Kansas, 66160, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Universitäts-Kinderspital beider Basel (UKBB)
Basel, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vimseltinib (a drug taken by mouth)
What this could lead to
If it works, this could offer a non-surgical treatment option for people with TGCT, shrinking tumors and easing symptoms.
What could go wrong
This is still an experimental drug. It may not shrink tumors enough, and side effects are possible. The trial is also relatively small (123 people).
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.